What are the WIPO ST.26 requirements for applications filed on or after July 1, 2022?
The MPEP 2422.06 section includes an important editor’s note regarding applications filed on or after July 1, 2022: “[Editor Note: This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b). See MPEP §§ 2412 – 2419 for…
Read MoreWho can make the required statement regarding the “Sequence Listing” and CRF?
The required statement regarding the information contained in the “Sequence Listing” and the separate Computer Readable Form (CRF) can be made by specific individuals. According to MPEP 2422.06: “Such a statement may be made by a registered practitioner, the applicant, an inventor, or the person who actually compares the sequence data on behalf of the…
Read MoreWhat is the requirement for submitting a separate computer readable form (CRF) of a “Sequence Listing”?
When a separate computer readable form (CRF) of a “Sequence Listing” is submitted in certain patent applications, a statement regarding the information contained in the “Sequence Listing” and the separate CRF is required. Specifically: For applications filed under 35 U.S.C. 111(a) or national stage applications submitted under 35 U.S.C. 371, where the “Sequence Listing” is…
Read MoreAre there exceptions to the requirement for submitting a separate CRF and statement?
Yes, there are exceptions to the requirement for submitting a separate Computer Readable Form (CRF) and the associated statement. According to MPEP 2422.06: “Note that, in an application filed under 35 U.S.C. 111(a), if a ‘Sequence Listing’ is filed as an ASCII plain text file via the USPTO patent electronic filing system or on a…
Read More